Articles From: Saratoga Investment Corp. to Report Fiscal Third Quarter 2015 Financial Results and Hold Conference Call to Savanna Energy Services Corp. Announces Appointment of Stella Cosby to Board of Directors


Computer scientists at Lawrence Livermore National Laboratory (LLNL) have combined innovative research in graph algorithms and data-intensive runtime systems to achieve world-class results on the Graph500 benchmark ( www.graph500.org ). The scientists’ work has been enabled by leading edge technology supplied by Saratoga Speed, Inc. and Mellanox® Technologies, Ltd.
Sign-up for Saratoga Speed and Mellanox Technologies Help Lawrence Livermore Lower the Barrier of Entry for Large Scale Graph Analytics investment picks
2014/10/27
A Piper Jaffray equity analyst cut his price target on Sarepta Therapeutics Inc. (SRPT) Monday.
Sign-up for Sarepta price target slashed by Piper Jaffray investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics today announced that it has initiated dosing in a confirmatory study of eteplirsen, the Company’s lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in ambulatory patients who meet specific criteria on their baseline 6-minute walk test score.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing of SRP-4053 in its first human trial, a Phase I/II study in Duchenne muscular dystrophy (DMD). This multiple-dose study will assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in DMD patients with genotypes amenable to exon-53 skipping.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sarepta’s NDA submission.
Sign-up for Sarepta Therapeutics Announces Regulatory Update on Eteplirsen investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and nine months ended September 30, 2014, and provided an update of recent corporate developments.
Sign-up for Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After more than three years of treatment, results of the 6-minute walk test (6MWT) at 168 weeks showed continued ambulation across all patients evaluable on the test, however all patients showed a decline in distance walked on this measure since the week 144 timepoint.
Sign-up for Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy investment picks
By Erin McCarthy Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.
Sign-up for Sarepta Therapeutics sees setback in Eteplirsen drug application investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014.
Sign-up for Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, December 2, 2014, beginning at 11:00 a.m. EST (8:00 a.m. PST / 4:00 p.m. GMT / 5:00 p.m. CET). Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer questions about Sarepta's DMD development program, including current and upcoming clinical trials.
Sign-up for Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that it is scheduled to present at the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 15, 2015 at 12:00 p.m. PST.
Sign-up for Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November.
Sign-up for Sarepta Therapeutics to Present Company Overview at Upcoming Conferences investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November.
Sign-up for Sarepta Therapeutics to Present Company Overview at Upcoming Conferences investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the Southern District of New York against Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT) and several officers and directors for acts taken during the period of April 21, 2014 to October 27, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Sarepta.
Sign-up for Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
2015/1/12
ATLANTA , Jan.
Sign-up for Sarvint Technologies Files Complaints for Patent Infringement for Wearable Technology investment picks
2015/1/14
SAS provides exploration update on Zone 4 deep drilling from the Holt Property Canada NewsWire 4.02 g/t Au over 37.3 metres including 7.64 g/t Au over 11.3 metres 21.37 g/t Au over 21.7 metres (18.71 g/t Au cut) TORONTO , Jan.
Sign-up for SAS provides exploration update on Zone 4 deep drilling from the Holt Property investment picks
2015/1/9
SAS reports 2014 annual production of 90,676 ounces of gold, and announces release date for Q4 2014 financial results and conference call Canada NewsWire TORONTO , Jan.
Sign-up for SAS reports 2014 annual production of 90,676 ounces of gold, and announces release date for Q4 2014 financial results and conference call investment picks
2014/12/22
JOHANNESBURG and LAKE CHARLES, Louisiana , December 22, 2014 /PRNewswire/ -- Sasol Limited (Sasol) (JSE: SOL; NYSE: SSL) today announced the completion of a US$4 billion credit facility for its ethane cracker and derivatives at its existing site in Lake Charles, Louisiana .
Sign-up for Sasol Announces Completion of US$4 Billion Credit Facility for its World-Scale Ethane Cracker and Derivatives Complex in Louisiana investment picks
2014/10/27
JOHANNESBURG, South Africa and LAKE CHARLES, Louisiana , October 27, 2014 /PRNewswire/ -- Today, Sasol Limited (JSE: SOL; NYSE: SSL) announced the final approval of an US$8.1 billion ethane cracker and derivatives complex at its existing site in Lake Charles, Louisiana .
Sign-up for Sasol Announces Final Investment Decision on World-Scale Ethane Cracker and Derivatives Complex in Louisiana investment picks
Global leader in RFID solutions launches Internet of Things initiative SATO enables higher availability for printers with SATO Online Services TOKYO , Dec.
Sign-up for SATO Deploys the Salesforce Customer Success Platform investment picks
Saudi Aramco Mobil Refinery Company Limited (SAMREF), a joint venture of Saudi Aramco and ExxonMobil , has completed construction of major desulfurization facilities, including a new hydrotreater, that dramatically cuts sulfur levels in gasoline and diesel.
Sign-up for Saudi Aramco and ExxonMobil Joint Venture Completes Clean Fuels Project investment picks
BETHESDA, Md.
Sign-up for Saul Centers Declares Quarterly Dividends investment picks
BETHESDA, Md.
Sign-up for Saul Centers, Inc. Announces Tax Treatment of 2014 Dividends investment picks
BETHESDA, Md.
Sign-up for Saul Centers, Inc. Reports Third Quarter 2014 Earnings investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982500001&sourceType=1 http://www.ccnmatthews.com/logos/20110527-100svy2.jpg CALGARY, ALBERTA --
Sign-up for Savanna Energy Services Corp. Announces Appointment of Stella Cosby to Board of Directors investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Saratoga Investment Corp. to Report Fiscal Third Quarter 2015 Financial Results and Hold Conference Call to Savanna Energy Services Corp. Announces Appointment of Stella Cosby to Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent